



## Current Strategies to Eliminate Latent HIV Infection

Guest Editors:

**Dr. Venkata Atluri**

Department of Biomedical  
Sciences, Meritus School of  
Osteopathic Medicine,  
Hagerstown, MD 21742, USA

**Dr. Venkateswara Gogulamudi**

Department of Internal Medicine,  
University of Utah, Salt Lake City,  
UT 84132, USA

Deadline for manuscript  
submissions:

**closed (30 April 2022)**

### Message from the Guest Editors

HIV infects a variety of cells in the body. To regulate or remove the HIV latent reservoir, several treatment options are being studied. These include either the total eradication of all persistent HIV (sterilization) or the immunological control of persistent HIV (functional cure). The “shock and kill” approach is the focus of contemporary sterilization cure research. Recently, clustered regularly interspersed short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) technology have been utilized to eradicate the HIV-1 latent reservoir by editing out the viral genome. In addition, many studies have focused on using nanotechnology-based anti-retroviral, CRISPR-Cas9, and other small molecule drug delivery targeting these HIV sanctuaries. The purpose of this thematic issue is to call for all basic and translational studies on exploring HIV-1 latency, novel drugs, and drug-delivery approaches targeting latent HIV infection in various parts of the body.





an Open Access Journal by MDPI

## Editors-in-Chief

### Prof. Dr. Peter E. Nielsen

Department of Cellular and  
Molecular Medicine, Faculty of  
Health and Medical Sciences,  
University of Copenhagen,  
Blegdamsvej 3C, DK-2200  
Copenhagen, Denmark

### Prof. Dr. Lukasz Kurgan

Department of Computer  
Science, Virginia Commonwealth  
University, Richmond, VA 23284,  
USA

## Message from the Editorial Board

*Biomolecules* is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)

## Contact Us

---

*Biomolecules* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/biomolecules  
biomolecules@mdpi.com  
X@Biomol\_MDPI